JAMA Pediatr:孕期高剂量补充VD可改善后的骨骼结局

2020-02-25 MedSci MedSci原创

与标准剂量相比,妊娠期高剂量维生素D补充可改善6岁以下的后代骨矿化,增加孕期摄入量可能对后代峰值骨量、骨折风险和骨质疏松风险有益

目前关于孕期母体维生素D水平与后代测量和骨矿化之间的关系仍存在争议,近日研究人员比较了妊娠期补充高剂量维生素D与标准剂量D对6岁以下后代骨骼结局的影响。

本次研究为前瞻性队列研究,包括623名孕妇及其584名子女,孕妇从妊娠第24周到出生后1周,分别补充2800 IU/D(高剂量)和400 IU/D(标准剂量)的维生素D。研究的主要终点为纵向人体测量学评估,包括6岁之前的身高、体重和体重指数,以及3岁和6岁时的骨矿物质含量(BMC)和骨密度(BMD),均采用双能X线扫描。

6岁时,517名儿童(89%)完成随访,其中男孩261人。3岁和6岁儿童的双能x线扫描结果表明,高维生素D组儿童的全身BMC较高:年龄、性别、身高和体重的平均差异调整(AMD)为11.5g;较高的头部以外BMC和BMD。低维生素D产妇和冬季分娩儿童受到的影响最为显著。事后分析中,研究人员发现高维生素D组骨折的发生率较低(n=23 vs n=36;发生率比,0.62),但在任何人体测量结果上没有差异。

与标准剂量相比,妊娠期高剂量维生素D补充可改善6岁以下的后代骨矿化,增加孕期摄入量可能对后代峰值骨量、骨折风险和骨质疏松风险有益。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942120, encodeId=10a41942120f8, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jun 05 05:53:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639370, encodeId=af9a16393e089, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 01 23:53:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728320, encodeId=3e751e28320a7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 16:53:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035928, encodeId=94e01035928c8, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Feb 25 21:53:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-06-05 amy0550
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942120, encodeId=10a41942120f8, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jun 05 05:53:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639370, encodeId=af9a16393e089, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 01 23:53:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728320, encodeId=3e751e28320a7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 16:53:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035928, encodeId=94e01035928c8, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Feb 25 21:53:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942120, encodeId=10a41942120f8, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jun 05 05:53:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639370, encodeId=af9a16393e089, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 01 23:53:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728320, encodeId=3e751e28320a7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 16:53:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035928, encodeId=94e01035928c8, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Feb 25 21:53:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-06-10 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942120, encodeId=10a41942120f8, content=<a href='/topic/show?id=065b1022341a' target=_blank style='color:#2F92EE;'>#高剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102234, encryptionId=065b1022341a, topicName=高剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=010d202, createdName=amy0550, createdTime=Fri Jun 05 05:53:00 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639370, encodeId=af9a16393e089, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Mon Jun 01 23:53:00 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728320, encodeId=3e751e28320a7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 16:53:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035928, encodeId=94e01035928c8, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Feb 25 21:53:00 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-02-25 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

JAMA:维生素D受体激活剂不能降低非继发性甲状旁腺功能亢进患者心血管事件风险

研究认为,对于非继发性甲状旁腺功能亢进且进行维持性血液透析的患者,接受维生素D受体激活剂治疗不会降低患者心血管事件风险

NEJM:高剂量维生素D用于危重VD缺乏患者

研究认为,对于缺乏维生素D的高危患者,早期大剂量肠内维生素D3治疗不能改善患者死亡率

JAMA:补充VD不能改善消化道肿瘤患者预后

研究认为,对于消化道肿瘤患者中,与安慰剂相比,补充维生素D并没有显著改善5年无复发生存率

GUT:围手术期低血浆VD水平与CRC不良预后相关

研究发现,CRC手术后循环中25OHD下降。血浆25OHD水平是一个预后生物标志物,低25OHD与不良预后相关,特别是在rs11568820 GG基因型患者中

GUT:结肠癌术后VD水平与预后

研究发现,CRC手术后循环中25OHD下降。血浆25OHD水平是一个预后生物标志物,低25OHD与不良预后相关,特别是在rs11568820 GG基因型患者中

JAMA:健康成人服用高剂量的VD对骨骼健康无益处

在健康成人中,研究不支持高剂量维生素D补充对骨骼健康有益